Patent Application: Reducing DPP-4 Activity Using Plants
Summary
The USPTO has published a new patent application (US20260083804A1) detailing methods and compositions for reducing DPP-4 activity using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, aims to provide health benefits such as increased GLP-1 levels and reduced visceral fat.
What changed
This document is a publication of a patent application filed with the USPTO, specifically application US20260083804A1. The application describes methods and compositions utilizing specific plants (Dichrostachys glomerata or Cissus quadrangularis) to reduce Dipeptidyl Peptidase-4 (DPP-4) activity or levels in mammals. Potential health benefits include increased GLP-1 levels, reduced visceral fat, and improved blood lipid and glucose profiles.
As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in therapeutic approaches for conditions related to DPP-4 activity, such as type 2 diabetes. Companies involved in pharmaceutical research and development, particularly in the areas of metabolic disorders and natural product-based therapeutics, should monitor the progress of this and similar patent applications.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR REDUCING DPP-4 ACTIVITY OR LEVELS IN A MAMMAL USING NATURALLY OCCURING PLANTS AND SPICES
Application US20260083804A1 Kind: A1 Mar 26, 2026
Inventors
Shil Kothari, Julius Enyoug Oben
Abstract
Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease DPP-4 activity or levels, visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing or decreasing DPP-4 activity or levels in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.
CPC Classifications
A61K 36/48 A61P 3/04 A61K 2236/17 A61K 2236/33
Filing Date
2024-09-26
Application No.
18898656
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.